Evaluation of patients with polycystic ovarian syndrome at a tertiary care center

Authors

  • Swapna Y. Department of Obstetrics and Gynecology, Deccan College of Medical Sciences, Hyderabad, Telangana, India
  • V. Srilakshmi Consultant, Area Hospital, Golkonda, Hyderabad, Telangana, India

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20193560

Keywords:

Hirsutism, Hyperandrogenism, Insulin resistance, Polycystic ovarian syndrome, Syndrome

Abstract

Background: It has been estimated that prevalence of PCOS ranges from 5-10% in reproductive females. Thus, it becomes most common endocrinopathy in this age group. Lack of ovulation and androgen over activity are key features of PCOS. The objective of this study was to patients with polycystic ovarian syndrome at a tertiary care center.

Methods: Present study was following up study with 200 cases of PCOS. Rotterdam criteria were used for the diagnosis of the PCOS. This criterion includes three things. First is woman having in last year <6 periods of menstruation. Second is testosterone value >0.6 ng/ml and third is each ovary having >12 follicles with increased size and volume. Those cases with hypothyroidism, adrenal tumors, congenital adrenal hyperplasia etc were excluded from the present study. Those on steroid therapy were also excluded. Detailed history and clinical examination were carried out for included cases as well as required investigations.

Results: Overall incidence of infertility was found as 27.9%. Out of these 200 cases, 44 (22%) had PCOS. Majority cases belonged to 20-24 years of age. Hirsutism was most common findings in clinical hyperandrogenism. Risk of insulin resistance syndrome was 4.79 times higher in obesity compared to not obese. Age, BMI, duration of infertility, ovarian volume, and menstrual pattern had effect on ovulation rate following laparoscopic ovarian drilling. Increasing duration of infertility and BMI had lower ovulation rate. Ovulation rate was highest when treated with clomiphene citrate alone than the combination therapy.

Conclusions: Women with obesity have more chances of having PCOS as seen from the present study.

References

Adams J, Polson DW, Abdulwahid N, Morris DV, Franks S, Mason HD, et al. Multifollicular ovaries clinical and endocrine response. Lancet. 1985;2(8469-70):1375-8.

Adams J, Polson DW, Franks S. Prevalence of polycystic ovarian syndrome in women with anovulation and idiopathic hirsutism. Br Med J. 1986;293(6543):355-9.

Bailey CJ, Turner RC. Metformin. N Engl J Med. 1996;334(9):574-9.

Balen AH, Conway GS, Kaltsas G, Techatrasak K, Manning PJ, West C et al. Polycystic ovary syndrome. The spectrum of the disorder in 1741 patients. Hum Reprod. 1995;10(8):2107-11.

Dunaif A1, Segal KR, Shelley DR, Green G, Dobrjansky A, Licholai T. Evidence for distinctive and intrinsic defects in insulin action in polycystic ovarian syndrome. Diabetes. 1992;41(10):1257.

Dunaif A. Insulin resistance and the polycystic ovarian syndrome; mechanism and implication for pathogenesis. Endocr Rev. 1997;18(6):774-800.

Franks S. Diagnosis of polycystic ovary syndrome. In defense of the Rotterdam criteria. J Clin Endocrinol Metab. 2006;91(3):786-9.

Dasgupta S, Mohan Reddy B. Present status of understanding on the genetic etiology on polycystic ovarian syndrome. J Postgrad Med. 2008;54(2):115-25.

Gjonnaess H. Polycystic ovarian syndrome treated by ovarian electrocautery through the laparoscope. Fertile Steril. 1984;41(1):20-5.

Moran LJ, Noakes M, Clifton PM et al. Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovarian syndrome. J Clin Endocrinol Metab. 2003;88(2):812-9.

Franks S. Polycystic ovary syndrome. N Engl J Med. 1995;333(13):853-61.

Goldzeiher JW. Polycystic ovarian disease. Fertile Steril. 1981;35(4):371-94.

Glueck CJ1, Dharashivkar S, Wang P, Zhu B, Gartside PS, Tracy Tet al. The obesity and extreme obesity, manifest by ages 20-24 years, continuing through 32-41 years in women, should alert physicians to the diagnostic likelihood of polycystic ovary syndrome as a reversible underlying endocrinopathy. Eur J Obstet Gynecol Reprod Biol. 2005;122(2):206-12.

Hammond M, Halme J, Talbert L. Factors affecting the pregnancy rate in clomiphene citrate induction of ovulation. Obstet Gynecol. 1983;62(2):196-202.

Zain MM, Jamaluddin R, Ibrahim A, Norman RJ. Comparison of clomiphene citrate, metformin or the combination of both for first line ovulation induction, achievement of pregnancy and live birth in Asian women with polycystic ovary syndrome. A randomized controlled trial. Fertile Steril. 2009;91(2):514-21.

Hull MGR. Polycystic ovarian disease. Clinical aspect and prevalence. Res Clin Forums. 1989;11:21.

Downloads

Published

2019-07-26

Issue

Section

Original Research Articles